Technical Analysis for IPHA - Innate Pharma S.A.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.08 | 7.22% | 0.14 |
IPHA closed up 7.22 percent on Monday, July 1, 2024, on 51 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 7.22% | |
| Wide Bands | Range Expansion | 7.22% | |
| Oversold Stochastic | Weakness | 7.22% | |
| New 52 Week Closing Low | Bearish | 4.52% | |
| Earnings Movers | Other | 4.52% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| 3x Volume Pace | about 10 hours ago |
| 5x Volume Pace | about 10 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/26/2024
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Immunotherapy Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Antibody Inflammatory Diseases Immunity
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.29 |
| 52 Week Low | 1.81 |
| Average Volume | 8,546 |
| 200-Day Moving Average | 2.54 |
| 50-Day Moving Average | 2.50 |
| 20-Day Moving Average | 2.33 |
| 10-Day Moving Average | 2.04 |
| Average True Range | 0.15 |
| RSI (14) | 39.02 |
| ADX | 38.17 |
| +DI | 13.28 |
| -DI | 33.38 |
| Chandelier Exit (Long, 3 ATRs) | 2.44 |
| Chandelier Exit (Short, 3 ATRs) | 2.37 |
| Upper Bollinger Bands | 2.97 |
| Lower Bollinger Band | 1.70 |
| Percent B (%b) | 0.3 |
| BandWidth | 54.30 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.0308 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.11 | ||||
| Resistance 3 (R3) | 2.11 | 2.09 | 2.11 | ||
| Resistance 2 (R2) | 2.09 | 2.09 | 2.10 | 2.10 | |
| Resistance 1 (R1) | 2.09 | 2.08 | 2.09 | 2.09 | 2.10 |
| Pivot Point | 2.07 | 2.07 | 2.08 | 2.08 | 2.07 |
| Support 1 (S1) | 2.07 | 2.07 | 2.07 | 2.07 | 2.06 |
| Support 2 (S2) | 2.05 | 2.06 | 2.06 | 2.06 | |
| Support 3 (S3) | 2.05 | 2.05 | 2.06 | ||
| Support 4 (S4) | 2.05 |
